{"id":"pegifn-2b","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"50-70","effect":"Fatigue"},{"rate":"40-60","effect":"Headache"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression / mood changes"},{"rate":"30-50","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201561","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylation extends the half-life of interferon-beta, allowing for less frequent dosing. The drug binds to interferon-beta receptors on immune cells and hepatocytes, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. This results in enhanced natural killer cell activity, increased MHC expression, and direct antiviral effects.","oneSentence":"PegIFN-2b is a pegylated interferon-beta that activates interferon-beta receptors to enhance innate and adaptive immune responses against viral infections and certain malignancies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:46.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C (in combination with ribavirin)"},{"name":"Multiple sclerosis (relapsing-remitting forms)"}]},"trialDetails":[{"nctId":"NCT02089685","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-17","conditions":"Renal Cell Carcinoma, Melanoma","enrollment":295},{"nctId":"NCT01756079","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-06","conditions":"Hepatitis C","enrollment":58},{"nctId":"NCT01432535","phase":"PHASE1","title":"Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11","conditions":"Renal Insufficiency","enrollment":25},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00686881","phase":"PHASE3","title":"Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":261},{"nctId":"NCT01770223","phase":"PHASE4","title":"A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00725751","phase":"","title":"Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Hepatitis C, Chronic","enrollment":353},{"nctId":"NCT00724893","phase":"","title":"Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":2430},{"nctId":"NCT01727271","phase":"PHASE4","title":"A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-08","conditions":"Hepatitis B","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Peginterferon alfa-2b","PegIntron","SCH 054031","Pegetron®","Pegylated interferon alfa-2b"],"phase":"marketed","status":"active","brandName":"PegIFN-2b","genericName":"PegIFN-2b","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"PegIFN-2b is a pegylated interferon-beta that activates interferon-beta receptors to enhance innate and adaptive immune responses against viral infections and certain malignancies. Used for Chronic hepatitis C (in combination with ribavirin), Multiple sclerosis (relapsing-remitting forms).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}